학술논문
Stable Gastric Pentadecapeptide BPC 157 Therapy for Primary Abdominal Compartment Syndrome in Rats.
Document Type
Academic Journal
Author
Tepes M; Department of Surgery, General Hospital Nasice, Nasice, Croatia.; Department of Clinical Medicine, Faculty of Dental Medicine and Health Osijek, Osijek, Croatia.; PhD Program Translational Research in Biomedicine-TRIBE, School of Medicine, University of Split, Split, Croatia.; Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia.; Gojkovic S; Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia.; Krezic I; Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia.; Zizek H; Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia.; Vranes H; Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia.; Madzar Z; Clinical Department of Surgery, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia.; Santak G; Department of Surgery, Faculty of Medicine, University of Osijek, Osijek, Croatia.; Batelja L; Department of Pathology, School of Medicine, University of Zagreb, Zagreb, Croatia.; Milavic M; Department of Pathology, School of Medicine, University of Zagreb, Zagreb, Croatia.; Sikiric S; Department of Pathology, School of Medicine, University of Zagreb, Zagreb, Croatia.; Kocman I; Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia.; Simonji K; Internal Diseases Clinic, Faculty of Veterinary Medicine Zagreb, Zagreb, Croatia.; Samara M; Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia.; Knezevic M; Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia.; Barisic I; Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia.; Lovric E; Department of Pathology, School of Medicine, University of Zagreb, Zagreb, Croatia.; Strbe S; Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia.; Kokot A; Department of Anatomy and Neuroscience, Faculty of Medicine, J.J. Strossmayer University of Osijek, Osijek, Croatia.; Sjekavica I; Department of Diagnostic and Interventional Radiology, University Hospital Centre, Zagreb, Croatia.; Kolak T; Department of Surgery, School of Medicine, University of Zagreb, Zagreb, Croatia.; Skrtic A; Department of Pathology, School of Medicine, University of Zagreb, Zagreb, Croatia.; Seiwerth S; Department of Pathology, School of Medicine, University of Zagreb, Zagreb, Croatia.; Boban Blagaic A; Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia.; Sikiric P; Department of Pharmacology, School of Medicine, University of Zagreb, Zagreb, Croatia.
Source
Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE
Subject
Language
English
ISSN
1663-9812
Abstract
Recently, the stable gastric pentadecapeptide BPC 157 was shown to counteract major vessel occlusion syndromes, i.e., peripheral and/or central occlusion, while activating particular collateral pathways. We induced abdominal compartment syndrome (intra-abdominal pressure in thiopental-anesthetized rats at 25 mmHg (60 min), 30 mmHg (30 min), 40 mmHg (30 min), and 50 mmHg (15 min) and in esketamine-anesthetized rats (25 mmHg for 120 min)) as a model of multiple occlusion syndrome. By improving the function of the venous system with BPC 157, we reversed the chain of harmful events. Rats with intra-abdominal hypertension (grade III, grade IV) received BPC 157 (10 µg or 10 ng/kg sc) or saline (5 ml) after 10 min. BPC 157 administration recovered the azygos vein via the inferior-superior caval vein rescue pathway. Additionally, intracranial (superior sagittal sinus), portal, and caval hypertension and aortal hypotension were reduced, as were the grossly congested stomach and major hemorrhagic lesions, brain swelling, venous and arterial thrombosis, congested inferior caval and superior mesenteric veins, and collapsed azygos vein; thus, the failed collateral pathway was fully recovered. Severe ECG disturbances (i.e., severe bradycardia and ST-elevation until asystole) were also reversed. Microscopically, transmural hyperemia of the gastrointestinal tract, intestinal mucosa villi reduction, crypt reduction with focal denudation of superficial epithelia, and large bowel dilatation were all inhibited. In the liver, BPC 157 reduced congestion and severe sinusoid enlargement. In the lung, a normal presentation was observed, with no alveolar membrane focal thickening and no lung congestion or edema, and severe intra-alveolar hemorrhage was absent. Moreover, severe heart congestion, subendocardial infarction, renal hemorrhage, brain edema, hemorrhage, and neural damage were prevented. In conclusion, BPC 157 cured primary abdominal compartment syndrome.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2021 Tepes, Gojkovic, Krezic, Zizek, Vranes, Madzar, Santak, Batelja, Milavic, Sikiric, Kocman, Simonji, Samara, Knezevic, Barisic, Lovric, Strbe, Kokot, Sjekavica, Kolak, Skrtic, Seiwerth, Boban Blagaic and Sikiric.)
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2021 Tepes, Gojkovic, Krezic, Zizek, Vranes, Madzar, Santak, Batelja, Milavic, Sikiric, Kocman, Simonji, Samara, Knezevic, Barisic, Lovric, Strbe, Kokot, Sjekavica, Kolak, Skrtic, Seiwerth, Boban Blagaic and Sikiric.)